TORONTO and HAIFA, Israel, April 04, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, Germany: J90) (“NurExone” or the “Company”) is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 3,543,238 units (“Units”) at a price of C$0.65 per